Alessandro Laganà
@lagana01.bsky.social
Assistant Professor at Mount Sinai, NY. Integrative cancer genomics, precision oncology, multiple myeloma.
http://laganalab.org
http://laganalab.org
This review examines the key players driving MM, bridging basic science and clinical insights, and providing a roadmap for precision medicine. 🔬 #CancerGenomics
December 21, 2024 at 10:41 PM
This review examines the key players driving MM, bridging basic science and clinical insights, and providing a roadmap for precision medicine. 🔬 #CancerGenomics
The study here: ashpublications.org/bloodneoplas...
Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma
Key PointsRNA-seq analysis reveals a 6-gene signature that stratifies patients with MM by their predicted response to venetoclax.This study proposes a nove
ashpublications.org
November 30, 2024 at 7:17 PM
The study here: ashpublications.org/bloodneoplas...
Our study bridges genomics and drug response, offering both predictive tools and a potential new strategy for patients resistant to venetoclax. #PrecisionMedicine #CancerResearch
November 30, 2024 at 7:17 PM
Our study bridges genomics and drug response, offering both predictive tools and a potential new strategy for patients resistant to venetoclax. #PrecisionMedicine #CancerResearch
1️⃣ Venetoclax works best for patients with t(11;14), but those with 1q gain are often resistant.
2️⃣ A six-gene signature helps predict response, providing a potential tool for precision medicine.
3️⃣ Excitingly, CDK7 inhibitors may help overcome resistance in patients with 1q gain.
2️⃣ A six-gene signature helps predict response, providing a potential tool for precision medicine.
3️⃣ Excitingly, CDK7 inhibitors may help overcome resistance in patients with 1q gain.
November 30, 2024 at 7:17 PM
1️⃣ Venetoclax works best for patients with t(11;14), but those with 1q gain are often resistant.
2️⃣ A six-gene signature helps predict response, providing a potential tool for precision medicine.
3️⃣ Excitingly, CDK7 inhibitors may help overcome resistance in patients with 1q gain.
2️⃣ A six-gene signature helps predict response, providing a potential tool for precision medicine.
3️⃣ Excitingly, CDK7 inhibitors may help overcome resistance in patients with 1q gain.
Excited to connect with researchers and clinicians—always learning and looking to collaborate!
November 30, 2024 at 7:04 PM
Excited to connect with researchers and clinicians—always learning and looking to collaborate!
We focus on high-risk myeloma, integrating genomics and clinical data to develop AI-driven solutions for personalized treatment. #PrecisionMedicine
November 30, 2024 at 7:04 PM
We focus on high-risk myeloma, integrating genomics and clinical data to develop AI-driven solutions for personalized treatment. #PrecisionMedicine
My lab studies the genomics and molecular drivers of multiple myeloma. Our mission? To uncover insights into treatment resistance and precision medicine using cutting-edge technologies like single-cell RNA-seq and spatial transcriptomics. 📍🗺️
November 30, 2024 at 7:04 PM
My lab studies the genomics and molecular drivers of multiple myeloma. Our mission? To uncover insights into treatment resistance and precision medicine using cutting-edge technologies like single-cell RNA-seq and spatial transcriptomics. 📍🗺️
It's Sky Follower Bridge:
chromewebstore.google.com/detail/sky-f...
chromewebstore.google.com/detail/sky-f...
Sky Follower Bridge - Chrome Web Store
Instantly find and follow the same users from your Twitter follows on Bluesky.
chromewebstore.google.com
November 7, 2024 at 10:21 PM
It's Sky Follower Bridge:
chromewebstore.google.com/detail/sky-f...
chromewebstore.google.com/detail/sky-f...